Dopaminergic drugs in development for Parkinson's disease.
Korczyn
Amos D
AD
Tel-Aviv University Medical School, Ramat-Aviv, Israel.
D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D018491:Dopamine Agonists / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism
D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa